Palatin Technologies (PTN) EBITDA Margin (2010 - 2026)

Palatin Technologies' (PTN) quarterly EBITDA Margin came in at 40.32% in Q1 2026, up 99.36% on a QoQ basis from 6315.75% in Q4 2025.

Palatin Technologies (PTN) EBITDA Margin (2010 - 2026) Analysis & Trends

Palatin Technologies (PTN) has 14 years of EBITDA Margin data on file, last reported at 40.32% in Q1 2026.

Quarterly EBITDA Margin changed N/A year-over-year to 40.32% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 50.67% (up 667255.0% YoY) and the FY2024 annual result came in at 501.02%, up 16814.0% from the prior year.
EBITDA Margin climbed to 40.32% in Q1 2026, from 6315.75% in the prior quarter.
In the past five years, EBITDA Margin ranged from a high of 57.67% in Q4 2023 to a low of 6315.75% in Q4 2025.
A 5-year average of 1485.87% and a median of 612.84% in 2023 frame the typical range for EBITDA Margin.
The widest YoY moves for EBITDA Margin: up 369025 bps in 2022, down 1033738 bps in 2022.
Tracing PTN's EBITDA Margin over 5 years: stood at 544.31% in 2022, then jumped by 111 bps to 57.67% in 2023, then sank by 4233 bps to 2383.45% in 2024, then sank by 165 bps to 6315.75% in 2025, then surged by 99 bps to 40.32% in 2026.
The last three EBITDA Margin figures came in at 40.32% (Q1 2026), 6315.75% (Q4 2025), and 52.79% (Q3 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	138.41 Bn	130.56 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	86.12 Bn	78.12 Bn	3.93 Bn	30.15%
3	Argenx Se	64.41 Bn	59.23 Bn	1.37 Bn	32.54%
4	Moderna	57.56 Bn	52.43 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	42.06 Bn	36.96 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	30.95 Bn	27.65 Bn	992.69 Mn	17.93%
7	BioNTech SE	27.48 Bn	9.09 Bn	668.28 Mn	-35.57%
8	Insmed	27.31 Bn	26.15 Bn	358.27 Mn	-0.36%
9	Royalty Pharma	27.04 Bn	26.20 Bn	-	19.75%
10	Palatin Technologies	40.25 Mn	40.25 Mn	-	-40.32%

Download Data